POM-V
Prescription Required
Companion Animal
Tessie 0.3 mg/ml Oral Solution for Dogs
Active ingredient: Tasipimidine
Form
Liquid
Species
Dogs
Manufacturer
Orion Corporation
VMD MA No.
06043/5004
The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Tasipimidine
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Tessie 0.3 mg/ml Oral Solution for Dogs — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
The product is intended for short term use but it can be safely administered for up to
9 consecutive days.
The product should be administered orally at a dose of 0.1 ml/kg bodyweight
(equivalent to 30 mcg/kg) in situational anxiety and fear in dogs triggered by noise or
owner departure.
If the product is intended for use in situations where the dog is meant to be alone
following the administration, a test dose should be given. Following administration of
the test dose the dog should be observed for 2 hours to make sure the selected dose
of the product is not associated with adverse reactions and that it is safe for the
treated dog to be left alone (see section 3.5).
Do not feed the dog for one hour before to one hour after treatment as absorption
may be delayed. A small treat can be given to ensure that the dog swallows the
solution. Water can be freely available.
Observe the dog. If the fear triggering event continues and the dog starts to show
signs of anxiety and fear again, re-dosing can be done when at least 3 hours has
passed from the previous dose. The product can be dosed up to 3 times within every
24 hours.
Dose reduction
If the dog appears drowsy, its movements are uncoordinated or it responds to its
owner’s call abnormally slowly after receiving treatment, the dose could be too high.
The subsequent dose should be reduced to 2/3 of the volume of the previous dose,
corresponding to 20 mcg/kg bodyweight. Dose reduction should be implemented
following veterinary advice only. When used concomitantly with clomipramine or
fluoxetine, tasipimidine dose should be reduced to 20 mcg/kg bodyweight (see
section 3.8).
Anxiety and fear triggered by noise:
The first dose should be given one hour before expected start of an anxiety triggering
stimulus, as soon as the dog shows the first signs of anxiety, or when the owner
detects a typical stimulus for eliciting anxiety or fear in the respective dog.
Anxiety and fear triggered by owner departure:
The dose should be given one hour before expected owner departure.
Instructions for administration:
1. REMOVE CAP
Remove the cap from the bottle (press down and twist). Save the cap
for reclosure.
2. CONNECT SYRINGE
Push the syringe tightly into the adapter located at the top of the bottle.
Use only the syringe provided with the product.
3. SELECT DOSE
Turn the bottle with the syringe in place upside down. Pull the plunger
out until the black line of correct dose (ml) can be seen under the grip
plate of the syringe barrel.
If the dog weighs more than 30 kg, the total dose will be given in two
separate doses as the syringe holds maximally 3.0 ml of solution.
The accuracy of the syringe is demonstrated only for doses of 0.2 ml
and higher. Dogs requiring doses lower than 0.2 ml can therefore not
be treated.
Don’t leave the filled dosing syringe unattended while preparing the
dog for administration.
4. GIVE DOSE
Gently place the syringe in the mouth of the dog and administer the
dose to the base of the tongue by gradually pressing the plunger until
the syringe is empty. Give the dog a small treat to ensure that the dog
swallows the solution.
5. BACK TO PACKAGE
Replace the cap and rinse the syringe with water when finished. Put
the syringe and bottle back to the secondary package and put them in
the refrigerator.
9 consecutive days.
The product should be administered orally at a dose of 0.1 ml/kg bodyweight
(equivalent to 30 mcg/kg) in situational anxiety and fear in dogs triggered by noise or
owner departure.
If the product is intended for use in situations where the dog is meant to be alone
following the administration, a test dose should be given. Following administration of
the test dose the dog should be observed for 2 hours to make sure the selected dose
of the product is not associated with adverse reactions and that it is safe for the
treated dog to be left alone (see section 3.5).
Do not feed the dog for one hour before to one hour after treatment as absorption
may be delayed. A small treat can be given to ensure that the dog swallows the
solution. Water can be freely available.
Observe the dog. If the fear triggering event continues and the dog starts to show
signs of anxiety and fear again, re-dosing can be done when at least 3 hours has
passed from the previous dose. The product can be dosed up to 3 times within every
24 hours.
Dose reduction
If the dog appears drowsy, its movements are uncoordinated or it responds to its
owner’s call abnormally slowly after receiving treatment, the dose could be too high.
The subsequent dose should be reduced to 2/3 of the volume of the previous dose,
corresponding to 20 mcg/kg bodyweight. Dose reduction should be implemented
following veterinary advice only. When used concomitantly with clomipramine or
fluoxetine, tasipimidine dose should be reduced to 20 mcg/kg bodyweight (see
section 3.8).
Anxiety and fear triggered by noise:
The first dose should be given one hour before expected start of an anxiety triggering
stimulus, as soon as the dog shows the first signs of anxiety, or when the owner
detects a typical stimulus for eliciting anxiety or fear in the respective dog.
Anxiety and fear triggered by owner departure:
The dose should be given one hour before expected owner departure.
Instructions for administration:
1. REMOVE CAP
Remove the cap from the bottle (press down and twist). Save the cap
for reclosure.
2. CONNECT SYRINGE
Push the syringe tightly into the adapter located at the top of the bottle.
Use only the syringe provided with the product.
3. SELECT DOSE
Turn the bottle with the syringe in place upside down. Pull the plunger
out until the black line of correct dose (ml) can be seen under the grip
plate of the syringe barrel.
If the dog weighs more than 30 kg, the total dose will be given in two
separate doses as the syringe holds maximally 3.0 ml of solution.
The accuracy of the syringe is demonstrated only for doses of 0.2 ml
and higher. Dogs requiring doses lower than 0.2 ml can therefore not
be treated.
Don’t leave the filled dosing syringe unattended while preparing the
dog for administration.
4. GIVE DOSE
Gently place the syringe in the mouth of the dog and administer the
dose to the base of the tongue by gradually pressing the plunger until
the syringe is empty. Give the dog a small treat to ensure that the dog
swallows the solution.
5. BACK TO PACKAGE
Replace the cap and rinse the syringe with water when finished. Put
the syringe and bottle back to the secondary package and put them in
the refrigerator.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in dogs with moderate or severe systemic disease (graded as ASA III or
greater), e.g. moderate to severe renal, liver or cardiovascular disease.
Do not use in dogs obviously sedated (shows signs of e.g. drowsiness,
uncoordinated movements, decreased responsiveness) from previous dosing.
excipients.
Do not use in dogs with moderate or severe systemic disease (graded as ASA III or
greater), e.g. moderate to severe renal, liver or cardiovascular disease.
Do not use in dogs obviously sedated (shows signs of e.g. drowsiness,
uncoordinated movements, decreased responsiveness) from previous dosing.
Dogs:
observed in non-anxious animals
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
Very common
(> 1 animal / 10 animals treated):
Emesis
Lethargy
Common
(1 to 10 animals / 100 animals
treated):
Behavioural disorder (Barking, Avoidance,
Increased reactivity)
Diarrhoea, Gastroenteritis, Nausea
Hypersensitivity reaction
Leucopenia
Ataxia, Sedation, Somnolence, Disorientation
Urinary incontinence
Anorexia, Pale mucous membranes, Polydipsia
Undetermined frequency
(cannot be estimated for the
available data):
Decreased heart rate
, Low blood pressure
Decreased body temperature
competent authority via the national reporting system. See the package leaflet for
respective contact details.
observed in non-anxious animals
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
Very common
(> 1 animal / 10 animals treated):
Emesis
Lethargy
Common
(1 to 10 animals / 100 animals
treated):
Behavioural disorder (Barking, Avoidance,
Increased reactivity)
Diarrhoea, Gastroenteritis, Nausea
Hypersensitivity reaction
Leucopenia
Ataxia, Sedation, Somnolence, Disorientation
Urinary incontinence
Anorexia, Pale mucous membranes, Polydipsia
Undetermined frequency
(cannot be estimated for the
available data):
Decreased heart rate
, Low blood pressure
Decreased body temperature
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Typical signs of anxiety and fear are panting, trembling, pacing (frequent change of
place, running around, restlessness), seeking people (clinging, hiding behind,
pawing, following), hiding (under furniture, in dark rooms), trying to escape, freezing
(absence of movements), refusing to eat food or treats, inappropriate urination,
inappropriate defecation, salivation, etc. These signs may be alleviated but may not
be completely eliminated.
In extremely nervous, excited or agitated animals, the levels of endogenous
catecholamines are often high. The pharmacological effect induced by alpha-2
agonists in such animals may be reduced.
Consideration should be given to use of a behavioural modification programme,
especially when dealing with a chronic condition such as separation anxiety.
Special precautions for safe use in the target species:
If the dog is sedated (shows signs of e.g. drowsiness, uncoordinated movements,
decreased responsiveness), do not leave the dog alone and withhold food and water.
The safety of administering tasipimidine to dogs younger than 6 months and older
than 14 years of age or weighing less than 3 kg has not been studied. Use only
according to a benefit-risk assessment by the responsible veterinarian.
The accuracy of the syringe is demonstrated only for doses of 0.2 ml and higher.
Dogs requiring doses lower than 0.2 ml can therefore not be treated.
As a decrease of body temperature can occur after the administration, the treated
animal should be kept at a suitable ambient temperature.
Tasipimidine may indirectly induce an increase of glycaemia. In diabetic animals, use
according to a benefit-risk assessment by the veterinarian.
In case of vomiting after intake of the oral solution, maintain the usual recommended
interval between two administrations (at least 3 hours) before administering the
product again.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Exposure to tasipimidine may cause adverse effects such as sedation, respiratory
depression, bradycardia and hypotension.
Avoid oral ingestion and skin contact including hand-to-mouth contact.
In order to prevent children from getting access to the product, don’t leave the filled
dosing syringe unattended while preparing the dog for administration. The used
syringe and the closed bottle should be returned to the original carton and stored out
of the sight and reach of children.
In case of accidental spillage onto skin, wash the exposed skin immediately with
water and remove contaminated clothes. In case of accidental ingestion, seek
medical advice immediately and show the package leaflet or the label to the
physician. Do not drive, as sedation and changes in blood pressure may occur.
This product may cause slight eye irritation. Avoid eye contact including hand-to-eye
contact. In case of eye contact, rinse the eyes immediately with water.
This veterinary medicinal product may cause hypersensitivity (allergy). People with
known hypersensitivity to tasipimidine or any of the excipients should avoid contact
with the veterinary medicinal product.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
place, running around, restlessness), seeking people (clinging, hiding behind,
pawing, following), hiding (under furniture, in dark rooms), trying to escape, freezing
(absence of movements), refusing to eat food or treats, inappropriate urination,
inappropriate defecation, salivation, etc. These signs may be alleviated but may not
be completely eliminated.
In extremely nervous, excited or agitated animals, the levels of endogenous
catecholamines are often high. The pharmacological effect induced by alpha-2
agonists in such animals may be reduced.
Consideration should be given to use of a behavioural modification programme,
especially when dealing with a chronic condition such as separation anxiety.
Special precautions for safe use in the target species:
If the dog is sedated (shows signs of e.g. drowsiness, uncoordinated movements,
decreased responsiveness), do not leave the dog alone and withhold food and water.
The safety of administering tasipimidine to dogs younger than 6 months and older
than 14 years of age or weighing less than 3 kg has not been studied. Use only
according to a benefit-risk assessment by the responsible veterinarian.
The accuracy of the syringe is demonstrated only for doses of 0.2 ml and higher.
Dogs requiring doses lower than 0.2 ml can therefore not be treated.
As a decrease of body temperature can occur after the administration, the treated
animal should be kept at a suitable ambient temperature.
Tasipimidine may indirectly induce an increase of glycaemia. In diabetic animals, use
according to a benefit-risk assessment by the veterinarian.
In case of vomiting after intake of the oral solution, maintain the usual recommended
interval between two administrations (at least 3 hours) before administering the
product again.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Exposure to tasipimidine may cause adverse effects such as sedation, respiratory
depression, bradycardia and hypotension.
Avoid oral ingestion and skin contact including hand-to-mouth contact.
In order to prevent children from getting access to the product, don’t leave the filled
dosing syringe unattended while preparing the dog for administration. The used
syringe and the closed bottle should be returned to the original carton and stored out
of the sight and reach of children.
In case of accidental spillage onto skin, wash the exposed skin immediately with
water and remove contaminated clothes. In case of accidental ingestion, seek
medical advice immediately and show the package leaflet or the label to the
physician. Do not drive, as sedation and changes in blood pressure may occur.
This product may cause slight eye irritation. Avoid eye contact including hand-to-eye
contact. In case of eye contact, rinse the eyes immediately with water.
This veterinary medicinal product may cause hypersensitivity (allergy). People with
known hypersensitivity to tasipimidine or any of the excipients should avoid contact
with the veterinary medicinal product.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
The use of other central nervous system depressants is expected to potentiate the
effects of tasipimidine and therefore an appropriate dose adjustment should be
made.
Tasipimidine has been studied in combination with clomipramine, fluoxetine,
dexmedetomidine, methadone, propofol and isoflurane.
In studies on laboratory dogs receiving a combination of fluoxetine (1.1–1.6 mg/kg
daily administration for 12 days) and tasipimidine (20 mcg/kg once, at day 12,
N = 4 dogs) or tasipimidine (20 mcg/kg) and clomipramine (1.2–2.0 mg/kg) both
administered twice daily during 4 days to 6 dogs, no clinical interactions have been
observed. When tasipimidine is used concomitantly with clomipramine or fluoxetine,
tasipimidine dose should be reduced to 20 mcg/kg bodyweight.
Should the dog have earlier required a dose reduction of tasipimidine to 20 mcg/kg,
this dose may be maintained. However, a test dose should be given according to the
instructions in section
effects of tasipimidine and therefore an appropriate dose adjustment should be
made.
Tasipimidine has been studied in combination with clomipramine, fluoxetine,
dexmedetomidine, methadone, propofol and isoflurane.
In studies on laboratory dogs receiving a combination of fluoxetine (1.1–1.6 mg/kg
daily administration for 12 days) and tasipimidine (20 mcg/kg once, at day 12,
N = 4 dogs) or tasipimidine (20 mcg/kg) and clomipramine (1.2–2.0 mg/kg) both
administered twice daily during 4 days to 6 dogs, no clinical interactions have been
observed. When tasipimidine is used concomitantly with clomipramine or fluoxetine,
tasipimidine dose should be reduced to 20 mcg/kg bodyweight.
Should the dog have earlier required a dose reduction of tasipimidine to 20 mcg/kg,
this dose may be maintained. However, a test dose should be given according to the
instructions in section
Store in a refrigerator (2°C – 8°C). Keep the bottle in the outer carton in order to
protect from light.
protect from light.
Replace the cap and rinse the syringe with water when finished. Put
the syringe and bottle back to the secondary package and put them in
the refrigerator.
3.10 Symptoms of overdose (and where applicable, emergency procedures and
antidotes)
The level and duration of sedation is dose dependent, and signs of sedation may
therefore particularly occur in case the dose is exceeded. Dogs receiving a high
overdose of the product have a higher risk of aspirating vomit due to the emetic and
CNS depressant effects associated with the active substance. A very high overdose
can potentially be life-threatening.
Reduced heart rate may be seen after administration of higher than recommended
doses of tasipimidine oral solution. Blood pressure decreases slightly below normal
levels. Respiration rate can occasionally decrease. Higher than recommended doses
of tasipimidine oral solution may also induce a number of other alpha-2 adrenoceptor
mediated effects, which include increase in blood pressure, decrease in body
temperature, lethargy, vomiting and a QT prolongation.
As demonstrated in a preclinical study, the effects of tasipimidine can be reversed
using a specific antidote, atipamezole (alpha-2 adrenoceptor antagonist). One hour
after treatment with tasipimidine at 60 mcg/kg body weight, an atipamezole dose of
300 mcg/kg bodyweight, corresponding to 0.06 ml/kg bodyweight of solution
containing 5 mg/ml, was administered intravenously. Results of this study
demonstrated that the effects of tasipimidine could be reversed. However, as the
half-life of tasipimidine exceeds that of atipamezole, some signs of tasipimidine
effects may reappear.
3.11 Special restrictions for use and special conditions for use, including
restrictions on the use of antimicrobial and antiparasitic veterinary
medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Not applicable
4.
the syringe and bottle back to the secondary package and put them in
the refrigerator.
3.10 Symptoms of overdose (and where applicable, emergency procedures and
antidotes)
The level and duration of sedation is dose dependent, and signs of sedation may
therefore particularly occur in case the dose is exceeded. Dogs receiving a high
overdose of the product have a higher risk of aspirating vomit due to the emetic and
CNS depressant effects associated with the active substance. A very high overdose
can potentially be life-threatening.
Reduced heart rate may be seen after administration of higher than recommended
doses of tasipimidine oral solution. Blood pressure decreases slightly below normal
levels. Respiration rate can occasionally decrease. Higher than recommended doses
of tasipimidine oral solution may also induce a number of other alpha-2 adrenoceptor
mediated effects, which include increase in blood pressure, decrease in body
temperature, lethargy, vomiting and a QT prolongation.
As demonstrated in a preclinical study, the effects of tasipimidine can be reversed
using a specific antidote, atipamezole (alpha-2 adrenoceptor antagonist). One hour
after treatment with tasipimidine at 60 mcg/kg body weight, an atipamezole dose of
300 mcg/kg bodyweight, corresponding to 0.06 ml/kg bodyweight of solution
containing 5 mg/ml, was administered intravenously. Results of this study
demonstrated that the effects of tasipimidine could be reversed. However, as the
half-life of tasipimidine exceeds that of atipamezole, some signs of tasipimidine
effects may reappear.
3.11 Special restrictions for use and special conditions for use, including
restrictions on the use of antimicrobial and antiparasitic veterinary
medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Not applicable
4.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Tasipimidine
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
VetBox
VetBox Flea & Worm Protection for Dogs
Vet-founded monthly parasite subscription. Flea, tick and worm protection delivered to your door. Founded by Dr Will Woodley, protecting 30,000+ pets.
From £9.99/month
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in behavioural
Related Medications
Clomicalm 20 mg Tablets for Dogs
POM-VClomipramine Hydrochloride
tablet
Rx
Dogs
Clomicalm 20 mg Tablets for Dogs
POM-VClomipramine Hydrochloride
tablet
Rx
Dogs
Clomicalm 5 mg Tablets for Dogs
POM-VClomipramine Hydrochloride
tablet
Rx
Dogs
Clomicalm 5 mg Tablets for Dogs
POM-VClomipramine Hydrochloride
tablet
Rx
Dogs
Clomicalm 80 mg Tablets for Dogs
POM-VClomipramine Hydrochloride
tablet
Rx
Dogs
Clomicalm 80 mg Tablets for Dogs
POM-VClomipramine Hydrochloride
tablet
Rx
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.